Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752903 | 0.97 | ALK (1.00) | ALK | |
| SCHEMBL16752929 | 0.97 | ALK (1.00) | ALK | |
| SCHEMBL16752884 | 0.97 | ALK (1.00) | ALK | |
| SCHEMBL18334849 | 0.96 | ALK (0.93) | ALK | |
| SCHEMBL18334854 | 0.96 | ALK (0.93) | ALK | |
| SCHEMBL16752917 | 0.95 | ALK (0.91) | ALK | |
| SCHEMBL16752915 | 0.95 | ALK (1.00) | ALK | |
| SCHEMBL16752895 | 0.95 | ALK (1.00) | ALK | |
| SCHEMBL16752902 | 0.95 | ALK (1.00) | ALK | |
| SCHEMBL16769601 | 0.95 | ALK (1.00) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146076-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| EP-4463571-A1 | ALK GENE FUSIONS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| US-20240093304-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-03-21 | — | — | US | claimed |
| EP-4327334-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | claimed |
| EP-4271831-A1 | ALK FUSION GENES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2023137447-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023077104-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | FOUNDATION MEDICINE, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023039539-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2022225995-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260120864-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | HOFFMANN LA ROCHE (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | PINOTBIO, INC. (KR) | 2015-06-04 | — | — | US | disclosed |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | PINOTBIO, INC. (KR) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260120864-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | TP53, BRCA1, VHL | ALK 196/4885 |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | MSH2, MSH6, PMS2 | ALK 2559/4885 |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | TNK2, NPM1, NEK4 | ALK 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.